NCT06960031

Brief Summary

This study aims to assess the residual tumoral activity versus the well ablation of اepatocellular carcinoma (HCC) post radiofrequency ablation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 30, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 28, 2025

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 7, 2025

Completed
Last Updated

May 20, 2025

Status Verified

May 1, 2025

Enrollment Period

4 months

First QC Date

April 28, 2025

Last Update Submit

May 18, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sensitivity of fluoro-2- deoxy-D-glucose (FDG) Positron emission tomography (PET) /computed tomography (CT) to predict hepatocellular carcinoma (HCC)

    Sensitivity of fluoro-2- deoxy-D-glucose (FDG) Positron emission tomography (PET) /computed tomography (CT) to predict hepatocellular carcinoma (HCC) will be measured.

    From 1 month to 3 months post radiofrequency ablation

Secondary Outcomes (3)

  • The value of fluoro-2- deoxy-D-glucose (FDG) Positron emission tomography (PET) /computed tomography (CT)

    From 1 month to 3 months post radiofrequency ablation

  • Serum Alpha-Fetoprotein (AFP) level

    From 1 month to 3 months post radiofrequency ablation

  • Mean diameter of ablated area and the mean of Liver standardized uptake value (SUvmax) .

    From 1 month to 3 months post radiofrequency ablation

Study Arms (1)

PET/CT

Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner. The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min.

Other: PET/CT technique

Interventions

Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner. The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min.

PET/CT

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This prospective cohort study will be carried out on 70 patients with hepatocellular malignancy at Tanta University Hospitals for a period from April 2025 to September 2025 after approval from institutional ethical committee.

You may qualify if:

  • Age from 40 to 75 years.
  • Both sexes.
  • Patients with hepatocellular carcinoma (HCC) and underwent radiofrequency ablation (RFA) .

You may not qualify if:

  • Patients with past history of contrast allergy.
  • Patients with blood glucose level \>200 mg/dl at the time of the study.
  • High serum creatinine\> 2 mg / dl.
  • Small lesions \< 10 mm.
  • Well differentiated hepatocellular carcinoma (HCC) lesions by pathology.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Diagnostic Radiology and Medical Imaging, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

First Submitted

April 28, 2025

First Posted

May 7, 2025

Study Start

December 30, 2024

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

May 20, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author

Locations